HLB Innovation's Verismo Unveils Solid Tumor CAR-T Preclinical Data at SITC, Claims Lower T-Cell Exhaustion and Toxicity
Predicted impact: Low· Actual: −4.2% vs sector, volume 0.3× normal (5 trading days)
Preclinical CAR-T data at a conference; early-stage with no revenue impact.